(Q37894446)

24 August 2017

1 reference

title

Management of type 2 diabetes: new and future developments in treatment (English)

1 reference

24 August 2017

0 references

1 reference

24 August 2017

Abd A Tahrani

1 reference

24 August 2017

Stefano Del Prato

series ordinal

1 reference

24 August 2017

Anthony H Barnett

series ordinal

1 reference

24 August 2017

language of work or name

English

0 references

publication date

24 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

378

1 reference

24 August 2017

issue

9786

1 reference

24 August 2017

page(s)

182-197

1 reference

Type 2 diabetes: principles of pathogenesis and therapy

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Mechanisms linking obesity to insulin resistance and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Pancreatic alpha-cell dysfunction in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Insulin resistance and beta-cell dysfunction in aging: the importance of dietary carbohydrate.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Glucose Intolerance and Aging: Evidence for Tissue Insensitivity to Insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Genetic dissection of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Roles for leptin receptor/STAT3-dependent and -independent signals in the regulation of glucose homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

The beta-cell in human type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Pancreatic islet inflammation in type 2 diabetes: from alpha and beta cell compensation to dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Hypothalamic AMP-activated protein kinase regulates glucose production

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Treating type 2 diabetes: how safe are current therapeutic agents?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Glycaemic control in type 2 diabetes: targets and new therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Oral Antidiabetic Agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

1 reference

7 January 2021

Meglitinide analogues for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

1 reference

7 January 2021

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Biology of incretins: GLP-1 and GIP

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Bromocriptine: old drug, new formulation and new indication

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

New treatments in type 2 diabetes: a focus on the incretin-based therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

The Physiology of Glucagon-like Peptide 1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

beta-cell failure in diabetes and preservation by clinical treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Incretin hormone mimetics and analogues in diabetes therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-b

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Small-molecule agonists for the glucagon-like peptide 1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

New therapies for diabesity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Recent advances in glucokinase activators for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

New hepatic targets for glycaemic control in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Allosteric activators of glucokinase: potential role in diabetes therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Glucokinase-activating GCKR polymorphisms increase plasma levels of triglycerides and free fatty acids, but do not elevate cardiovascular risk in the Ludwigshafen Risk and Cardiovascular Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Free fatty acid receptors: emerging targets for treatment of diabetes and its complications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Insulin secretion defects of human type 2 diabetic islets are corrected in vitro by a new reactive oxygen species scavenger

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Beta- and alpha-cell dysfunction in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

A novel glucagon receptor antagonist, NNC 25-0926, blunts hepatic glucose production in the conscious dog.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Pharmacokinetic and pharmacodynamic modeling of a monoclonal antibody antagonist of glucagon receptor in male ob/ob mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Treating insulin resistance: future prospects.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Discovery of a Small Molecule Insulin Mimetic with Antidiabetic Activity in Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

A novel hydroxyfuroic acid compound as an insulin receptor activator. Structure and activity relationship of a prenylindole moiety to insulin receptor activation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

A novel small molecule that directly sensitizes the insulin receptor in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Oral Insulin-Mimetic Compounds That Act Independently of Insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Active sugar transport in health and disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

SGLT2 inhibition--a novel strategy for diabetes treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Glucokinase (GCK) mutations in hyper- and hypoglycemia: Maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Regulation of glucose-6-phosphatase gene expression by insulin and metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Prolonged inhibition of glycogen phosphorylase in livers of Zucker Diabetic Fatty rats models human glycogen storage diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Recent advances in antidiabetic drug therapies targeting the enteroinsular axis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Redefining the role of thiazolidinediones in the management of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Potential remains for PPAR-targeted drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Effect of bromocriptine on maturity onset diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

CNS regulation of glucose homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Who Would Have Thought It? An Operation Proves to Be the Most Effective Therapy for Adult-Onset Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Bariatric surgery for morbid obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Obesity, gut hormones, and bariatric surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Gastric bypass increases energy expenditure in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Bariatric surgery and taste: novel mechanisms of weight loss.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Increases in morbid obesity in the USA: 2000-2005

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

The effect of bilio-pancreatic diversion on type 2 diabetes in patients with BMI <35 kg/m2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

Surgical treatment of morbid obesity: mid-term outcomes of the laparoscopic ileal interposition associated to a sleeve gastrectomy in 120 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

How do we define cure of diabetes?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960207-9

7 January 2021

10.1016/S0140-6736(11)60207-9

Identifiers

DOI

1 reference

24 August 2017

1 reference